万基遗传 MYGN 深 沪
等待开盘 05-12 09:30:00 美东时间
4.255
-0.030
-0.70%
华盛通- 最 高4.44
- 今 开4.26
- 成交量 54.37万股
- 最 低 3.75
- 昨 收 4.285
- 总市值 34.19万
- 52周最高 8.59
- 市盈率 静 --
- 换手率 676.78%
- 52周最低 3.75
- 委 比 -35.74%
- 总股本 8.03万
- 历史最高 50.44
- 量 比 0.49
- 振 幅 16.10%
- 历史最低 1.10
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
02-24 18:21
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Myriad Genetics's Earnings: A Preview
Myriad Genetics (NASDAQ:MYGN) is gearing up to announce its quarterly earnings ...
02-21 03:01
Myriad Genetics Q3 Sales $205.700M Beat $204.897M Estimate
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst consensus estimate of $204.897 million by 0.39 percent. This is a 3.56 percent decrease over sales of $213.300 million
2025-11-04 05:08
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
2025-11-03 19:11
万基遗传达成合作推进癌症诊断技术的协议
美股周三早盘，基因检测与精准医疗公司万基遗传（Myriad Genetics，MYGN）股价下跌4.1%，此前有报道称该公司已与全球领先的液体活检公司ANGLE plc（场外市场代码：ANPCF）达成合作推进癌症诊断技术的协议。 双方将利用ANGLE公司的Parsortix®系统捕获癌细胞进行DNA分析。此项合作旨在提升肿瘤学诊断精准度并拓展治疗方案选择。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-08-20 22:51
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
This breakthrough screening combines
2025-06-03 13:00
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
The MONSTAR-SCREEN 3 study demonstrated 100% ctDNA detection at baseline and 60% of patients positive one month post-surgery had ultra-sensitive tumor fractions, highlighting the importance of Myriad's Precise MRD ultra-sensitive testing in early recurrence detection.
2025-06-02 13:00
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Castle Biosciences presents study showing DecisionDx-Melanoma reduces mortality risk by 32% in melanoma patients, improving survival through precise risk assessment and personalized treatment.
2025-05-29 20:30
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Myriad Genetics将展示七项新研究，包括两项关于分子残留病（MRD）的研究，旨在评估多癌种ctDNA检测和治疗监测的进展。此外，公司还介绍了其扩展的基因面板和新的MRD测试产品，进一步推进精准肿瘤学和患者护理。
2025-05-27 20:05
